Latest News and Press Releases
Want to stay updated on the latest news?
-
NESS ZIONA, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
-
First subject dosed in pivotal Phase III program evaluating Epsolay® in subjects with papulopustular rosacea Two Phase III trials expected to enroll a total of 700 subjects Top-line data expected...
-
NESS ZIONA, Israel, May 29, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and...
-
NESS ZIONA, Israel, May 15, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and...
-
NESS ZIONA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, announced today that it filed its Annual Report for 2017 on Form...
-
NESS ZIONA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
-
NESS ZIONA, Israel, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing...
-
NESS ZIONA, Israel, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing...
-
NESS ZIONA, Israel, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing...
-
TWIN Achieved Primary and Secondary Efficacy Endpoints with Statistical Significance and a Favorable Tolerability Profile Subject to End of Phase 2 Meeting to be Scheduled with the FDA, Commencement...